Caris Life Sciences, Inc. $CAI Stock Position Lifted by Clearbridge Investments LLC

Clearbridge Investments LLC grew its position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 2.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,416,207 shares of the company’s stock after buying an additional 34,977 shares during the period. Clearbridge Investments LLC owned about 0.50% of Caris Life Sciences worth $38,209,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CAI. UBS Group AG lifted its holdings in Caris Life Sciences by 825.9% during the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after buying an additional 1,948,107 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Caris Life Sciences by 57,052.2% during the 4th quarter. BNP Paribas Financial Markets now owns 685,826 shares of the company’s stock worth $18,504,000 after buying an additional 684,626 shares during the last quarter. TD Asset Management Inc lifted its holdings in Caris Life Sciences by 248.1% during the 4th quarter. TD Asset Management Inc now owns 773,852 shares of the company’s stock worth $20,879,000 after buying an additional 551,516 shares during the last quarter. Zevenbergen Capital Investments LLC bought a new position in Caris Life Sciences during the 4th quarter worth approximately $14,655,000. Finally, Seven Grand Managers LLC lifted its holdings in Caris Life Sciences by 395.1% during the 4th quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock worth $13,358,000 after buying an additional 395,095 shares during the last quarter.

Insider Buying and Selling

In other Caris Life Sciences news, Director Jeff L. Vacirca bought 31,050 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the transaction, the director directly owned 49,671 shares in the company, valued at $802,186.65. The trade was a 166.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 50.00% of the stock is currently owned by corporate insiders.

Caris Life Sciences Trading Up 5.1%

Shares of NASDAQ CAI opened at $16.96 on Wednesday. Caris Life Sciences, Inc. has a 12-month low of $14.19 and a 12-month high of $42.50. The company has a current ratio of 7.05, a quick ratio of 6.52 and a debt-to-equity ratio of 0.64. The company has a market cap of $4.79 billion and a P/E ratio of -2.23. The business has a 50 day moving average of $17.80.

Caris Life Sciences announced that its board has approved a stock repurchase plan on Monday, June 8th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 2.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several analysts recently issued reports on CAI shares. Robert W. Baird set a $22.00 price target on Caris Life Sciences in a report on Friday, May 8th. New Street Research started coverage on Caris Life Sciences in a report on Friday, May 8th. They issued a “market perform” rating on the stock. Canaccord Genuity Group cut their price target on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Friday, March 13th. BTIG Research cut their price target on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. cut their price target on Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Caris Life Sciences presently has an average rating of “Hold” and a consensus price target of $27.56.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.